Every one of those 1 sits in a single category, ai-models. Of the tracked stories, 1 of 1 also mention Brandon Fornwalt, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 AI story that mention Tempus ECG-PH, all published on August 25, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Tempus ECG-PH
Every one of those 1 sits in a single category, ai-models. Of the tracked stories, 1 of 1 also mention Brandon Fornwalt, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 AI story that mention Tempus ECG-PH, all published on August 25, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 6 AI stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Tempus ECG-PH. Shared-story counts are live from our verified record — not editorial picks.
Tempus's ECG-PH AI model analyzes raw 12-lead ECG waveforms for binary signs associated with elevated mPAP >20 mmHg, receiving FDA 510(k) clearance and marking the company's third cardiovascular AI device. This matters for ML teams as regulatory acceptance of diagnostic AI broadens.